Form 4: Flora Growth CEO's Stock Appreciation Rights Repriced to Lower Exercise Price

Flora Growth Corp. CEO Clifford Starke's Stock Appreciation Rights (SARs) were amended with shareholder approval to significantly lower their exercise prices, impacting over 1.6 million underlying common shares.

Summary

• Clifford Starke, CEO and Director of Flora Growth Corp. (FLGC), reported changes in his beneficial ownership of derivative securities via a Form 4 filing.
• The filing indicates an amendment to previously granted Stock Appreciation Rights (SARs), effectively repricing them to a lower exercise price.
• A total of 1,028,665 SARs, originally granted on December 15, 2023, with an exercise price of $1.21, were disposed of and simultaneously re-acquired with a new exercise price of $0.58.
• Additionally, 575,319 SARs, originally granted on August 14, 2024, with an exercise price of $0.915, were disposed of and re-acquired with a new exercise price of $0.58.
• The total number of SARs affected by this repricing is 1,603,984 (1,028,665 + 575,319).
• The SARs vest in 9 equal installments, subject to specific stock price criteria being met prior to each tranche vesting.
• The SARs have a post-termination exercise period of one year.
• The amendments to the SARs were made with shareholder approval.

Sentiment

Score: 4

Explanation: The repricing of executive SARs to a lower exercise price is generally viewed as a negative signal for shareholders, as it can indicate past underperformance and potentially dilute shareholder value, despite being beneficial for the executive and having received shareholder approval.

Positives

• The repricing of Stock Appreciation Rights to a lower exercise price is beneficial for CEO Clifford Starke, potentially increasing the intrinsic value of his equity incentives.
• Shareholder approval for the SAR amendments indicates adherence to corporate governance procedures for significant compensation changes.

Negatives

• The repricing of executive equity incentives, particularly to a significantly lower exercise price, can be viewed negatively by shareholders as it may dilute existing shareholder value or signal underperformance that necessitated the repricing.
• The effective reduction in the hurdle for executive compensation may raise questions about alignment with long-term shareholder interests if not tied to robust performance metrics.

Risks

• Potential shareholder dissatisfaction or perception of misalignment between executive compensation and company performance due to the repricing of SARs.
• The stock price criteria for vesting, while mentioned, are not detailed, posing a risk if they are easily achievable or do not sufficiently incentivize significant stock price appreciation.

Future Outlook

The repriced Stock Appreciation Rights are subject to vesting in 9 equal installments, contingent on specific stock price criteria being met prior to each tranche vesting, and have expiration dates extending to December 2034 and August 2034.

Management Comments

• The SARs granted to the reporting person on December 15, 2023, and August 14, 2024, were amended, with shareholder approval, to have a lower exercise price.

Industry Context

Repricing of executive equity incentives often occurs in industries or companies experiencing significant stock price declines, aiming to restore the motivational value of compensation. While common, it can be a contentious issue, particularly if not clearly justified by performance or market conditions.

Comparison to Industry Standards

• Repricing of executive stock options or SARs is generally viewed with caution by institutional investors and governance bodies, as it can be perceived as a 'reset' that benefits management at the expense of shareholders who have endured stock price depreciation.
• While shareholder approval was obtained, the practice itself, especially when the stock price has fallen, contrasts with best practices that emphasize long-term alignment and avoiding 'underwater' option repricing without significant new performance hurdles.

Corporate Governance

Related Party Transactions

• The amendment and repricing of Stock Appreciation Rights for CEO Clifford Starke constitutes a related party transaction, as it involves a significant compensation change for a key executive.

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution or a 'reset' of executive incentives at a lower hurdle, despite shareholder approval.
• CEO (Clifford Starke): Positive impact due to improved potential value of his equity incentives, making them more likely to be 'in the money'.

Next Steps

• Future vesting of the repriced SARs in 9 equal installments, subject to stock price criteria.

Key Dates

Recommendation

Keywords

Flora Growth Corp, FLGC, SEC Form 4, Stock Appreciation Rights, SARs, executive compensation, repricing, insider transaction, Clifford Starke, corporate governance